We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toInnovations-in-Managing-Global-Clinical-Supplies

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

Innovations in Managing Global Clinical Supplies

    Session Chair(s)
      Mark  Wade

      Mark Wade

      • Executive Director
      • Transperfect, United States
    This session is focused on examining the choke points of label creation and execution. Virtually all studies have an international component, what methodologies and technologies can be leveraged to streamline an already intricate process? This session will examine an exciting new eLabel initiative and communicate what TransCelerate is doing to assist with industry uptake and influencing health authorities. In addition this session will focus on the future or randomization and trial supply management and understanding the shift to self-service, configurable tools. This session will review industry trends and approaches and benefits to moving your organization towards the future with RTSM capabilities.
    Learning Objective : - Understand the options and benefits of utilizing eLabeling to enhance site efficiency and enhance patient centricity. - Discuss approaches, considerations when planning a study, and potential add-on technologies which can further improve productivity at sites. - Describe some of the misconceptions around the near-term viability for an eLabel solution.
      Mark  Wade

      Uncorking the Bottleneck in Labeling for Investigational Medicinal Products in Multicultural Clinical Trials

      Mark Wade

      • Executive Director
      • Transperfect, United States
      Hans  Von Steiger

      The Near-Term Viability and Benefits of eLabels for Clinical, Sites, and Patients

      Hans Von Steiger

      • Director / Team Leader
      • Pfizer Inc, United States
      Jennifer  Bush, MS

      The Future of Randomization and Trial Supply Management

      Jennifer Bush, MS

      • Director, Life Sciences Product Strategy
      • Oracle, United States